Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Dr Friederike Schlürmann a Medical Oncologist from University Hospital of Brest and Quimper in France, discuss the clinical implementation of targeted and immunotherapies for advanced renal cell carcinoma (RCC).
In this podcast, the two experts discuss data from key trials CHECKMATE 214 (ipilimumab and nivolumab), KEYNOTE 426 (axitinib and pembrolizumab), CHECKMATE 9ER (cabozantinib and nivolumab), CLEAR (Lenvatinib and pembrolizumab) and COSMIC 313 (cabozantinib plus nivolumab and ipilimumab) and the implications for clinical practice.
They also discuss management of toxicities associated with combination treatments, including dosing strategies to ensure the patient remains on optimal treatment and improved education for patients and clinicians so that they recognise side effects and how to manage them.
In this medical education podcast episode, Prof. Peter Galle and Prof. Amit Singal discuss the use of VEGFR-TKIs in the treatment of advanced or...
Prof. Josep Llovet and Prof. Stephen L. Chan discuss a very interesting topic about the use of the VEGFR TKIs monotherapy in the treatment...
COR2ED Educación Médica: Pablo Peinado, coordinador de Enfermería de Investigación, y la Dra. Elena Castro, oncóloga médica, quienes trabajan en el Hospital Universitario Virgen...